297 results on '"Choi, Kwangmin"'
Search Results
2. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
3. Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
4. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis
5. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
6. RUNX represses Pmp22 to drive neurofibromagenesis.
7. Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis.
8. Natural and Artificial Aging Effects on the Deformation Behaviors of Al–Mg–Zn Alloy Sheets.
9. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia
10. Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.
11. Hepatic Ago2-mediated RNA silencing controls energy metabolism linked to AMPK activation and obesity-associated pathophysiology.
12. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth
13. Schwann cells modulate nociception in neurofibromatosis 1
14. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK
15. Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.
16. A molecular basis for neurofibroma-associated skeletal manifestations in NF1
17. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs
18. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation
19. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies
20. STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma
21. The Influence of Grain Size on the Mechanical Damping Behavior of Aluminum
22. Mechanical Properties of Aluminium-Based Nanocomposite Reinforced with Fullerenes
23. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
24. Data from Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes
25. Data from Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
26. Supplementary Figure 1 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
27. Supplementary Methods from Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes
28. Supplementary Table S2 from Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes
29. Supplementary Tables from Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
30. Supplementary Figure S1-13 and Supplementary Table S1,3 from Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes
31. Data from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
32. Supplementary Figures from Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
33. Supplementary Figure 4 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
34. Supplementary Table 1 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
35. Supplementary Table 2 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
36. Supplementary Table and Figure Legends from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
37. Supplementary Figure 2 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
38. Supplementary Figure 3 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
39. Supplementary Data from Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST
40. Data from Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST
41. Data from In Vivo Regulation of TGF-β by R-Ras2 Revealed through Loss of the RasGAP Protein NF1
42. Supplementary Figures 1-5, Table 1 from In Vivo Regulation of TGF-β by R-Ras2 Revealed through Loss of the RasGAP Protein NF1
43. Schwann cells modulate nociception in neurofibromatosis 1
44. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia
45. Mechanical damping behavior of Al/C60-fullerene composites with supersaturated Al–C phases
46. The Transcriptional Repressor ZBTB4 Regulates EZH2 Through a MicroRNA-ZBTB4-Specificity Protein Signaling Axis
47. A Circulating Microbial Metabolite Drives the Clonal Expansion of Pre-Leukemic Cells
48. IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
49. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment
50. Defective transcription elongation in a subset of cancers confers immunotherapy resistance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.